- Research article
- Open Access
- Open Peer Review
HIF1α isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation
© Monsef et al; licensee BioMed Central Ltd. 2010
- Received: 18 January 2010
- Accepted: 21 July 2010
- Published: 21 July 2010
Neuroendocrine (NE) differentiation in prostate cancer has been correlated with a poor prognosis and hormone refractory disease. In a previous report, we demonstrated the presence of immunoreactive cytoplasmic hypoxia inducible factor 1α (HIF1α), in both benign and malignant NE prostate cells. HIF1α and HIF1β are two subunits of HIF1, a transcription factor important for angiogenesis. The aim of this study was to elucidate whether the cytoplasmic stabilization of HIF1α in androgen independent NE differentiated prostate cancer is due to the presence of certain HIF1α isoforms.
We studied the HIF1α isoforms present in 8 cases of benign prostate hyperplasia (BPH) and 43 cases of prostate cancer with and without NE differentiation using RT-PCR, sequencing analysis, immunohistochemistry and in situ hybridization.
We identified multiple isoforms in both benign and malignant prostate tissues. One of these isoforms, HIF1α1.2, which was previously reported to be testis specific, was found in 86% of NE-differentiated prostate tumors, 92% of HIF1α immunoreactive prostate tumors and 100% of cases of benign prostate hyperplasia. Immunohistochemistry and in situ hybridization results showed that this isoform corresponds to the cytoplasmic HIF1α present in androgen-independent NE cells of benign and malignant prostate tissue and co-localizes with immunoreactive cytoplasmic HIF1β.
Our results indicate that the cytoplasmic stabilization of HIF1α in NE-differentiated cells in benign and malignant prostate tissue is due to presence of an HIF1α isoform, HIF1α1.2. Co-localization of this isoform with HIF1β indicates that the HIF1α1.2 isoform might sequester HIF1β in the cytoplasm.
- Vascular Endothelial Growth Factor
- Androgen Receptor
- Benign Prostate Hyperplasia
- LNCaP Cell
- Prostate Tissue
Neuroendocrine (NE) cells in benign and malignant prostate tissue are characterized by expression of the NE marker chromogranin A and their specific morphology, including cytoplasmic extensions and dendritic processes. In addition, they lack androgen receptor and are therefore androgen-independent [1, 2]. The majority of prostatic adenocarcinomas contain tumor cells with NE features which are present focally throughout the tumors. Several studies have shown that an increased number of NE cells in prostate cancer tissue and increased levels of circulating chromogranin A, an NE marker usually expressed in NE cells, are associated with a poor prognosis, tumor progression and androgen-independent disease [1, 2]. It has been hypothesized that NE cells might affect the growth and proliferation of prostate tumors in an androgen receptor-independent way, probably through the secretion of NE peptides and autocrine/paracrine signaling pathways [1, 3–6]. NE tumor cells in prostate cancer may also have a role in tumor angiogenesis. Increased expression of vascular endothelial growth factor (VEGF) in malignant NE cells and a higher density of microvessels around nests of such cells compared to areas of prostate cancer without these cells have been reported . In a previous study, we demonstrated the presence of cytoplasmic hypoxia inducible factor 1α (HIF1α) in a population of NE cells in benign and malignant prostate tissues . HIFs are a family of transcription factors that are essential for angiogenesis and the adaptation of cells to hypoxia in both physiological and pathological processes [9, 10]. The possible mechanisms behind HIF1α stabilization and the function of cytoplasmic HIF1α in NE cells of benign and malignant prostate tissues are not known. However, the complicated regulation of HIFs has been extensively studied in recent years. HIF1, which is composed of two subunits, HIF1α and β, binds to the HRE of promoter regions and activates many genes involved in angiogenesis, glycolysis and anaerobic metabolism. In normoxia, the HIF1α subunit is hydroxylated on specific proline residues (402 and 564) within the oxygen dependent domain (ODD) by specific oxygen-sensitive prolyl hydroxylases and, then ubiquitinated through the von Hippel-Lindau (VHL) dependent pathway and degraded instantly in the proteasome [9, 10]. However, in hypoxic conditions, HIF1α is stabilized by impaired function of these prolyl hydroxylases. After its interaction with a series of small proteins, such as P300 and CBP, the HIF1α and β complex translocates to the nucleus using its nuclear localizing signal (NLS) domains at C-and N-terminus and activates the cell's adaptive response to hypoxia [9, 10]
There have been several previous reports on HIF1α isoforms lacking several exons or displaying different exons than the wild type protein. Some of these isoforms encode cytoplasmic HIF1α protein or proteins with altered transcriptional activity compared to the wild type protein. Regarding the N-terminal domain, two HIF1α isoforms with different first exons have been identified: HIF1α1.2, a protein with a different first and second exon which is 59 amino acids shorter than wild type HIF1α and encodes a cytoplasmic protein specifically expressed in the human testis ; HIF1α1.3, which is present in activated T-lymphocytes and encodes a functional protein with weaker transcriptional activity that the wild type protein . At the C-terminal domain, isoforms lacking either exon 12  or exons 11 and 12  have been reported. Both isoforms have been shown to be stable cytoplasmic proteins and inhibit the function of full-length HIF1α. Another shorter HIF1α isoform lacking exon 14 has also been reported . This isoform was shown to be 3-fold less active than full-length HIF1α.
The aim of this study was to elucidate the mechanism behind the cytoplasmic stabilization of HIF1α in NE cells of benign and malignant prostate tissues. We have investigated whether the cytoplasmic HIF1α corresponds to any specific known isoform. Based on the sequences published by the National Center for Biotechnology Information (NCBI), we designed primers to amplify known HIF1α isoforms and determined their presence in benign prostate hyperplasia and prostate cancer with and without NE differentiation.
Characteristics of patients whose samples were used in this study
Nr. of cases
Benign prostate hyperplasia
Non - determined
Non - determined
Hormone refractory adenocarcinoma
Adenocarcinoma with non determined hormonal state
RNA preparation, RT-PCR and sequence analysis
Primers used for amplification/sequencing and biotinylated oligonucleotide probes
Forward primer 5'-3'
Reverse primer 5'-3'
Size of amplified fragment lengths (bp)
Probe HIF1α 1.2
Antisense, Biotin-GC AAGATATGTG CAAGACAC-Biotin
Sense, Biotin-GTGT CTTGCACAT ATCTTGC-Biotin
Biotinylated anti sense and sense olignucleotide probes were designed and purchased from Invitrogen (Table 2). Tissues were fixed in 4% formaldehyde, 4-μm-thick sections were cut and mounted on silanized slides (DAKO S3003), dewaxed with xylene for 10 min and rehydrated stepwise with 100% ethanol for 3 min and 70% ethanol for 3 min. Endogenous peroxidase and biotin were blocked with peroxidase blocking solution (DAKO REAL, S2023) and biotin blocking system (DAKO, X0590) for 15 min each. The sections were then permeabilized with Proteinase K (DAKO S3020) and washed with Tris-buffered saline three times. Biotinylated probes designed for HIF1α1.2 (Table 2, Invitrogen) were mixed in hybridization buffer (50% formamide) at a concentration of 200 ng/ml. Probes were added to the sections, which were then covered with coverslips and heated at 92°C for 5 min. Hybridization was carried out in a humid chamber at 37°C overnight. The sections were then washed in 2 × SSC for 10 min followed by three washes in Tris-buffered saline. For detection of hybridization signals, the Gen Point Tyramid Signal Amplification System (Dako, K0620) with chromogenic substrate (3.3'diaminobenzidine) was used according to the manufacturer's instructions.
Antibodies used for immunostaining
Androgen receptor, AR
Double immunostaining was performed with combinations of primary antibodies for androgen receptor/chromogranin A and HIF1β/HIF1αA3. Double immunostaining kit (PicTure™ Invitrogen, catalog nr. 87-9999) was used, according to the manufacturer's instructions. Goat anti mouse IgG HRP (horseradish peroxidase) conjugate used with DAB (3,3' Diaminobenzidine) produced a brown stain. Goat anti Rabbit IgG-AP polymer conjugate used with Fast red produced a red stain.
A broad range of HIF1αisoforms exists in benign and malignant prostate tissues
The frequency of HIF1α isoforms in benign prostate hyperplasia and prostate cancer with and without NE.
Adenocarcinoma immunopositive for HIF1α
Adenocarcinoma immunonegative for HIF1α
Adenocarcinoma with NE
Adenocarcinoma Without NE
HIF1α 1.3 was not detected in any of our study cases (Table 4, Fig.1c). Since inflammation was rare in our specimen, this further verifies a report showing the presence of this isoform of HIF 1α in activated lymphocytes. However, we lacked positive control for HIF1α1.3.
Tο investigate various isoforms with alternative splicing of exons 11 to 13, we used forward primers located in the middle of exon 10 and reverse primers located in the middle of exon 13. We noted one strong band of 220 bp and a weaker band of 340 bp (Fig. 1d). Sequence analysis of the shorter band showed only part of exons 10 and 13, indicating the presence of an HIF1α isoform without exons 11 and 12. Sequence analysis of the weaker band of 340 bp was not possible, but the size of the band corresponds to an isoform lacking exon12. These two isoforms were found in both benign and malignant cases. In one case of benign prostate hyperplasia and three cases of malignant prostate tissue, we also detected a band at 720 bp, which might correspond to HIF1α containing exons 11 and 12. As a control, we analyzed LNCaP cells, which showed a strong band of 720bp (Fig. 1g, lane 5). Sequence analysis verified that the band corresponds to exons 10, 11 and 12 as well as a part of exon 13.
To further investigate the presence of exon 12 in benign and malignant prostate tissues, we designed primers located in the beginning and end of exon 12 (Table 2). We identified exon 12 in all study cases (Fig. 1e). We conclude that the first experiment using primers located in exons 10 and 13 was not optimal to detect the longer HIF1α isoform containing exon 12. We also conclude that in most cases of benign prostate hyperplasia and prostate cancers, the HIF1α isoform containing exon 12 is expressed at very low levels since LNCaP cells had high signals with the same primers (Fig. 1g, lane 5).
HIF1α variants with and without exon 14 (HIF1α14+ and 14-) were detected in all cases of benign prostate hyperplasia and prostate cancer. With primers located in exons 13 and 15, we detected two bands corresponding to these two isoforms (Fig. 1f).
LNCaP cells were used as control for analysis of HIF1α1.1, HIF1α12+/-, and HIF1α14+/-. HIF1α 1.2 and 1.3 were not detected in these cells (Fig. 1g, lanes 1,2,3 and 6).
Cytoplasmic HIF1α in NE cells from prostate tumors has an different N-terminus than the wild type protein
Co-localization of HIF1α and HIF1β in androgen receptor-negative benign and malignant NE-like cells of the prostate
Immunostaining for HIF1β showed cytoplasmic staining in NE-like cells of benign prostate tissue (Fig. 2i). In order to investigate whether the immunoreactive HIF1β co-localizes with HIF1α in benign prostate tissue, we selected two cases of benign prostate hyperplasia for double immunostaining. We observed co-localization of cytoplasmic HIF1α with cytoplasmic HIF1β in all NE cells of the benign prostate tissue (53 cells counted) (Fig. 2j). We also investigated the localization of HIF1α and HIF1β using immunostaining of serial sections of two cases with NE and non-NE prostate tumors. HIF1β was seen in approximately 80%-100% of HIF1α-positive NE-differentiated tumor cells (Figs. 2e and 2f). In addition, double staining in malignant HIF1α-immunopositive cells showed that these cells were immunonegative for androgen receptor (Fig. 2g). In non-NE prostate tumors we found no detectable cytoplasmic HIF1β immunostaining. Only weak nuclear HIF1β staining was observed in these tumors (data not shown).
In situ hybridization shows the presence of HIF1.2αin NE-differentiated benign and malignant prostate cells
In situ hybridization was performed on serially cut paraffin sections from two cases of benign and four cases of malignant prostate cancer. Two cases of adenocarcinomas were previously shown to contain cells with cytoplasmic HIF1α and NE marker, chromogranin. The other two cases were negative for cytoplasmic HIF1α and NE marker. In adjacent sections, the majority of HIF1α positive cells in both benign and malignant cells (93% versus 89%) also displayed increased HIF1α1.2 specific mRNA levels (Figs. 3a,c, g, i, j). Fifty cells were counted in the benign cases, and 300 cells were counted in the malignant tissue. The HIF1α-negative cells had low or no detectable mRNA levels of HIF1α (Figs. 3e and 3f). These findings suggest that HIF1α1.2 corresponds to the isoform encoding cytoplasmic HIF1α in both benign and malignant prostate tissues.
HIF1α, a major transcription factor essential in tumorigenesis, has been shown to be over-expressed in many types of tumors, including prostate cancer [16–18]. Neo-angiogenesis occurs in an uncoordinated fashion in malignant tumors, leading to hypoxia, inactivation of prolyl hydroxylases and inhibition of HIF1α degradation, which, in turn, activates HIF1α . HIF1α protein has also been shown to be stabilized under normoxic conditions by growth factor stimulation or due to mutations in the VHL protein . The accumulation of HIF1α protein has been reported to be an early event in prostate cancer and high-grade prostatic intraepithelial neoplasia (HGPIN) [21, 22]. The accumulation of wild type HIF1α should lead to its nuclear transport, unless regulatory parts are defective or missing. One possible explanation for the cytoplasmic stabilization of the protein is the presence of certain HIF1α isoforms. Indeed, in this study, we have shown that a broad range of HIF1α isoforms are present in both benign prostate hyperplasia and prostate tumors. We have shown by PCR, immunohistochemistry and in situ hybridization that the previously reported testis-specific isoform, HIF1α 1.2 corresponds to cytoplasmic HIF1α in NE-differentiated benign and malignant prostate cells. HIF1α1.2, which lacks one of the NLS domains responsible for nuclear transport, was shown to accumulate in the cytoplasm and has also been shown in a previous study to have inhibitory effects on full-length HIF in human sperms . The authors of that study speculated that inhibition of full-length HIF1α might be essential for the function of hypoxic sperm. A similar function for cytoplasmic HIF1α in benign and malignant prostate cells might be considered. In addition, co-localization of cytoplasmic HIF1α and HIF1β in this study indicates that this isoform might sequester HIF1β in the cytoplasm. Other reports confirm a similar function for cytoplasmic HIF1α. Stimulation of HEK293 cells with zinc induces a cytoplasmic spliced variant of HIF1α without exon 12 . This 557-amino-acid isoform was shown to sequester HIF1β in the cytoplasm and therefore to inhibit wild type HIF1α. Due to a frame shift mutation, the isoform is shortened and lacks both trans activating domains and the C-terminal nuclear localizing signal domain. Another cytoplasmic spliced variant of human HIF1α (516 amino acids in length) represents a stable, short isoform without exons 11 and 12 . Similarly to the variant lacking only exon 12, this isoform was identified as a dominant negative due to its association with HIF1β in the cytoplasm.
Recent studies have shown an association between hypoxia inducible factor and androgen receptor. The androgen receptor activates HIF1α, leading to upregulation of hypoxia inducible factor gene products [24, 25]. In addition, hypoxia has been shown to increase androgen receptor sensitivity  and androgen receptor induced expression of the human PSA gene in a prostate cancer cell line . Malignant NE cells which have been shown to increase in number after hormonal treatment, are usually androgen independent and only occasionally express androgen receptor and PSA . As, we have shown here, the NE differentiated tumor cells display an isoform with a possible inhibitory effect on the wild type HIF1α protein, indicating that the androgen independent malignant NE cells might also be independent of HIF1α for their survival and tumorogenesis.
Malignant NE cells have been correlated with increased microvessel density in prostate tumors and display increased expression of VEGF, an important angiogenic regulatory factor. The functional implication of cytoplasmic HIF1α and its relationship to VEGF remain to be elucidated. HIF1α is a key regulatory transcription factor of VEGF, but VEGF has also been shown to be regulated by other transcriptions factors. For example, RaIA uppregulates VEGF-C in prostate cancer cells during androgen ablation  and STAT3 binds to the VEGF promoter and directly regulates VEGF . If cytoplasmic HIF1α in NE cells exerts an inhibitory effect on full-length HIF1α, this might indicate that VEGF is up-regulated in NE cells by other transcription factors.
In summary, our results suggest that cytoplasmic HIF1α in androgen independent NE cells of benign prostate tissue and non NE differentiated prostate tumors, corresponds to HIF1α1.2 isoform. Co-localization of this isoform with immunoreactive cytoplasmic HIF1β indicates that the HIF1α 1.2 isoform, which lacks one of the protein's nuclear translocation signals, may sequester HIF1β in the cytoplasm.
The authors declare that they have no competing interests.
Financial support: This study was supported by the Gunnar Nilsson Cancer Foundation, grant no. P95/07, The Swedish Research Council, grant no. k2007-G7X-20443-01-3 and the Swedish Childhood Cancer Foundation grant no. PROJ07/013.
- Vashchenko N, Abrahamsson PA: Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005, 47 (2): 147-155. 10.1016/j.eururo.2004.09.007.View ArticlePubMedGoogle Scholar
- Bonkhoff H, Fixemer T: Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype. Pathologe. 2005, 26 (6): 453-460. 10.1007/s00292-005-0791-0.View ArticlePubMedGoogle Scholar
- Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA: Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate. 2004, 59 (3): 328-336. 10.1002/pros.10374.View ArticlePubMedGoogle Scholar
- Moody TW, Chan D, Fahrenkrug J, Jensen RT: Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des. 2003, 9 (6): 495-509. 10.2174/1381612033391621.View ArticlePubMedGoogle Scholar
- Carraway RE, Hassan S: Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress. Regul Pept. 2007, 141 (1-3): 140-153. 10.1016/j.regpep.2006.12.027.View ArticlePubMedGoogle Scholar
- Siddiqui EJ, Shabbir M, Mikhailidis DP, Thompson CS, Mumtaz FH: The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol. 2006, 176 (4 Pt 1): 1648-1653. 10.1016/j.juro.2006.06.087.View ArticlePubMedGoogle Scholar
- Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K: VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. Faseb J. 2000, 14 (13): 2087-2096. 10.1096/fj.99-1049com.View ArticlePubMedGoogle Scholar
- Monsef N, Helczynski L, Lundwall A, Pahlman S: Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands. Prostate. 2007, 67 (11): 1219-1229. 10.1002/pros.20594.View ArticlePubMedGoogle Scholar
- Semenza GL: Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life. 2008, 60 (9): 591-597. 10.1002/iub.93.View ArticlePubMedGoogle Scholar
- Zhou J, Schmid T, Schnitzer S, Brune B: Tumor hypoxia and cancer progression. Cancer Lett. 2006, 237 (1): 10-21. 10.1016/j.canlet.2005.05.028.View ArticlePubMedGoogle Scholar
- Depping R, Hagele S, Wagner KF, Wiesner RJ, Camenisch G, Wenger RH, Katschinski DM: A dominant-negative isoform of hypoxia-inducible factor-1 alpha specifically expressed in human testis. Biol Reprod. 2004, 71 (1): 331-339. 10.1095/biolreprod.104.027797.View ArticlePubMedGoogle Scholar
- Lukashev D, Sitkovsky M: Preferential expression of the novel alternative isoform I.3 of hypoxia-inducible factor 1alpha in activated human T lymphocytes. Hum Immunol. 2008, 69 (7): 421-425. 10.1016/j.humimm.2008.05.004.View ArticlePubMedPubMed CentralGoogle Scholar
- Chun YS, Choi E, Yeo EJ, Lee JH, Kim MS, Park JW: A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J Cell Sci. 2001, 114 (Pt 22): 4051-4061.PubMedGoogle Scholar
- Chun YS, Choi E, Kim TY, Kim MS, Park JW: A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem J. 2002, 362 (Pt 1): 71-79. 10.1042/0264-6021:3620071.View ArticlePubMedPubMed CentralGoogle Scholar
- Gothie E, Richard DE, Berra E, Pages G, Pouyssegur J: Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. J Biol Chem. 2000, 275 (10): 6922-6927. 10.1074/jbc.275.10.6922.View ArticlePubMedGoogle Scholar
- Kimbro KS, Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 2006, 13 (3): 739-749. 10.1677/erc.1.00728.View ArticlePubMedGoogle Scholar
- Korkolopoulou P, Patsouris E, Konstantinidou AE, Pavlopoulos PM, Kavantzas N, Boviatsis E, Thymara I, Perdiki M, Thomas-Tsagli E, Angelidakis D, et al: Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol. 2004, 30 (3): 267-278. 10.1111/j.1365-2990.2003.00535.x.View ArticlePubMedGoogle Scholar
- Luo Y, He DL, Ning L, Shen SL, Li L, Li X: Hypoxia-inducible factor-1alpha induces the epithelial-mesenchymal transition of human prostatecancer cells. Chin Med J (Engl). 2006, 119 (9): 713-718.Google Scholar
- Semenza GL, Shimoda LA, Prabhakar NR: Regulation of gene expression by HIF-1. Novartis Found Symp. 2006, 272: 2-8. full_text. discussion 8-14, 33-16View ArticlePubMedGoogle Scholar
- Page EL, Chan DA, Giaccia AJ, Levine M, Richard DE: Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell. 2008, 19 (1): 86-94. 10.1091/mbc.E07-06-0612.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhong H, Semenza GL, Simons JW, De Marzo AM: Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev. 2004, 28 (2): 88-93. 10.1016/j.cdp.2003.12.009.View ArticlePubMedGoogle Scholar
- Hao P, Chen X, Geng H, Gu L, Chen J, Lu G: Expression and implication of hypoxia inducible factor-1alpha in prostate neoplasm. J Huazhong Univ Sci Technolog Med Sci. 2004, 24 (6): 593-595. 10.1007/BF02911365.View ArticlePubMedGoogle Scholar
- Chun YS, Lee KH, Choi E, Bae SY, Yeo EJ, Huang LE, Kim MS, Park JW: Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. Cancer Res. 2003, 63 (24): 8700-8707.PubMedGoogle Scholar
- Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL: The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res. 2005, 11 (21): 7658-7663. 10.1158/1078-0432.CCR-05-0460.View ArticlePubMedGoogle Scholar
- Rudolfsson SH, Bergh A: Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1alpha. J Endocrinol. 2008, 196 (1): 11-19. 10.1677/JOE-07-0272.View ArticlePubMedGoogle Scholar
- Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, Hidalgo AA, Ip C, Park EM, Yoon SY, Park YM: Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res. 2006, 66 (10): 5121-5129. 10.1158/0008-5472.CAN-05-1341.View ArticlePubMedGoogle Scholar
- Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y, Sakaue M, Sano T, Kitagawa T, Himeno S, et al: Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res. 2007, 5 (4): 383-391. 10.1158/1541-7786.MCR-06-0226.View ArticlePubMedGoogle Scholar
- Rinaldo F, Li J, Wang E, Muders M, Datta K: RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation. Oncogene. 2007, 26 (12): 1731-1738. 10.1038/sj.onc.1209971.View ArticlePubMedGoogle Scholar
- Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002, 21 (13): 2000-2008. 10.1038/sj.onc.1205260.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/385/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.